补阳还五汤加味联合强阿片药物治疗难治性癌痛的临床观察
Clinical Observation of Modified Buyang Huanwu Decoction Combined with Strong Opioids in the Treatment of Refractory Cancer Pain
刘丽 1张换友 1周姝妍 1陈成1
作者信息
- 1. 眉山市中医医院,四川眉山 620010
- 折叠
摘要
目的 观察补阳还五汤加味联合强阿片药物治疗难治性癌痛的临床疗效.方法 选取60例难治性癌痛患者作为研究对象,随机分为治疗组及对照组各30例,对照组使用强阿片药物治疗,治疗组在此基础上联合补阳还五汤加味治疗,比较2组患者疼痛评分、药物剂量、生命质量、血清疼痛介质及不良反应.结果 治疗后,治疗组疼痛评分、吗啡日用量均较对照组降低(P＜0.05);治疗组患者身体功能、疼痛、失眠方面生命质量更高(P＜0.05);2组血清疼痛介质PGE2、5-HT、NPY、P物质水平均较治疗前降低(P＜0.05),且治疗组降低程度优于对照组(P＜0.05);2组不良反应差异无统计学意义(P＞0.05).结论 补阳还五汤加味联合强阿片药物治疗难治性癌痛能更好地缓患者疼痛程度,提高病人生命质量,降低血清疼痛介质水平.
Abstract
Objective:To observe the clinical effect of Buyang Huanwu Decoction combined with strong opioids in the treatment of refractory cancer pain.Methods:60 patients with refractory cancer pain were selected as research ob-jects and randomly divided into treatment group and control group,30 cases each group.The control group was treated with strong opioid drugs,and the treatment group was supplemented with Buyang Huanwu Decoction on the basis of the control group.The pain score,herbal dose,quality of life,serum pain mediators and adverse reactions were compared between the two groups.Results:After treatment,the pain score and daily dose of morphine in the treatment group were lower than those in the control group(P＜0.05).The quality of life in the treatment group was higher in physical function,pain and insomnia(P＜0.05).The levels of serum pain mediator PGE2,5-HT,NPY and substance P in the 2 groups were lower than those before treatment(P＜0.05),and the reduction degree in the treatment group was better than that in control group(P＜0.05).There was no significant difference in the adverse reactions between the two groups(P＞0.05).Conclusion:Buyang Huanwu Decoction combined with strong opioids can better relieve the pain degree of patients with refractory cancer pain,improve the quality of life of patients,and reduce the level of ser-um pain mediators.
关键词
难治性癌痛/补阳还五汤/临床观察Key words
Refractory Cancer Pain/Buyang Huanwu Decoction/Clinical Observation引用本文复制引用
基金项目
四川省中医药管理局科研项目(2021MS261)
出版年
2024
NETL
NSTL
万方数据